



NDA 203159/S-002

SUPPLEMENT APPROVAL

Bayer HealthCare Pharmaceuticals, Inc.
Attention: Jo-Ann Ruane
Deputy Director, Global Regulatory Affairs
PO Box 1000
Montville, NJ 07045-1000

Dear Ms. Ruane:

Please refer to your Supplemental New Drug Application (sNDA) dated and received March 8, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Skyla (levonorgestrel-releasing intrauterine system) 13.5 mg.

We also refer to our approval letter dated September 13, 2013, which contained the following errors: The original approval letter referenced "Changes Being Effected" and should have read "Prior Approval Supplement" also, the incorrect product label was attached to the Approval Letter.

This replacement approval letter and label incorporates the correction of this error. The effective approval date will remain September 13, 2013, the date of the original approval letter.

This "Prior Approval" supplemental new drug application provides changes to the Highlights that summarizes information in Warnings and Precautions Section 5.6, Perforation, and patient label, 'Should I check that Skyla is in place?'

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Charlene Williamson, Regulatory Project Manager, at (301) 796-1025.

Sincerely,

{See appended electronic signature page}

Audrey Gassman, M.D.
Deputy Director
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling